Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

NDA FilingXPOVIOruxolitinibPositive

AI Analysis

Summary

Karyopharm Therapeutics submitted a supplemental NDA to the FDA for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis treatment under the Accelerated Approval Pathway with Priority Review requested.

Outcome Details

sNDA submitted under Accelerated Approval Pathway; Priority Review requested

Importance:7/10

Sentiment:

0.60

FDA submissionsupplemental NDAaccelerated approvalpriority reviewmyelofibrosiscombination therapy

Related Companies

$KPTI

Read the original article

Published by PR Newswire Biotech on August 31, 2026 11:30 AM

Read Original